Osmotic delivery of therapeutic compounds by solubility enhancement
First Claim
1. An oral osmotic pharmaceutical delivery dosage form, comprising at least one pharmaceutically active agent that has solubility limitations, and meglumine as a solubilizing agent.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention is directed to the oral osmotic delivery of therapeutic compounds that have limited solubility in an aqueous environment due to inherent hydrophobicity or to saturation limitations in the core of the osmotic system. The present invention is suitable for the osmotic delivery of glipizide and other hydrophobic drugs, but runs the spectrum to other therapeutic agents with higher aqueous solubilities, yet having a solubility limitation in an osmotic dosage unit due to high drug load.
94 Citations
51 Claims
- 1. An oral osmotic pharmaceutical delivery dosage form, comprising at least one pharmaceutically active agent that has solubility limitations, and meglumine as a solubilizing agent.
-
9. An osmotic pharmaceutical delivery dosage form, comprising:
-
(a) a semipermeable wall that maintains its integrity during pharmaceutical delivery and which has at least one passageway through it connecting the core of the dosage form with the external environment; and
(b) a core surrounded by the wall, said core containing a composition comprising;
(i) at least one pharmaceutically active agent that has solubility limitations, (ii) at least one non-swelling solubilizing agent that enhances the solubility of the pharmaceutically active agent to such an extent that the drug is solubilized before release from the dosage form; and
(iii) at least one non-swelling osmotic agent. - View Dependent Claims (10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)
-
- 27. An solid pharmaceutical composition, comprising a pharmaceutically active agent that has solubility limitations, together with meglumine and a high HLB surfactant as co-solubilizing agents.
- 35. A process for preparing a solid oral dosage form, comprising mixing one or more pharmaceutically active agents with meglumine and a binder solution, spraying to form granules, drying the granules in a fluid bed, dry screening the granules, lubricating the granules by adding a lubricating agent, followed by dry blending to effect adequate distribution of the tablet lubrication agents, and compressing on a rotary tablet press, thereby obtaining a solid oral dosage form.
- 38. A method for delivering a pharmaceutical dosage unit to a mammal in need thereof, comprising orally administering an osmotic pharmaceutical delivery dosage form, said dosage form comprising at least one pharmaceutically active agent that has solubility limitations, and meglumine as a solubilizing agent.
- 45. A method for treating an abnormal condition in a mammal, comprising orally administering an osmotic dosage form that has a core comprising at least one pharmaceutically active agent that has solubility limitations and meglumine as a solubilizing agent to said mammal, and monitoring the effectiveness of the treatment.
Specification